Pacira BioSciences, Inc. (PCRX) Q4 FY25 Earnings Call

Volume momentum is improving, but 2026 guidance implies measured growth and lower margins than 2025's record level [28][41][44].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-02
Length44 minutes
EPS$0.32
EPS consensus$0.60
Revenue$196.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All PCRX earnings ยท Back to PCRX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.